{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:13:05Z","timestamp":1786975985195,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd005474","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000}}],"reference-count":157,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005474.pub2","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T10:16:37Z","timestamp":1510827397000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Zuclopenthixol dihydrochloride for schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Edward J","family":"Bryan","sequence":"first","affiliation":[{"name":"NHS Foundation Trust; Sheffield Health and Social Care; Fulwood House Old Fulwood Road Sheffield UK S10 3TH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Ann","family":"Purcell","sequence":"additional","affiliation":[{"name":"Market Surgery; General Practitioner; Warehouse Lane Wath Rotherham UK S63 7RA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Leeds Community Healthcare NHS Trust; Child and Adolescent Mental Health Service; Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"10.1002\/14651858.CD005474.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1600-0447.1981.tb06216.x","article-title":"Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)-trans(E)-clopenthixol","volume":"294","author":"Aaes-Jorgensen","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eurpsy.2005.07.006","article-title":"Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence","volume":"21","author":"Arango","year":"2006","journal-title":"European Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005474.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/S0924-977X(04)80350-X","article-title":"Antipsychotic treatment adherence and violence in schizophrenia outpatients: a randomized prospective trial","volume":"14","author":"Bombin","year":"2004","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0004|cit4","first-page":"149","article-title":"A double blind multicentre comparison of oral zuclopenthixol and oral chlorpromazine in the treatment of acute psychosis","volume":"n\/a","author":"Balasubramanian","year":"1991","journal-title":"British Journal of Clinical Research"},{"issue":"9","key":"10.1002\/14651858.CD005474.pub2-BIB0005|cit5","first-page":"473","article-title":"Comprehensive clinical studies with thiothixene","volume":"36","author":"Ban","year":"1975","journal-title":"Diseases of the Nervous System"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0006|cit6","first-page":"118","article-title":"Thiothixene versus chlorprothixene versus clopenthixol","volume":"6","author":"Lehmann","year":"1970","journal-title":"Psychopharmacology Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0007|cit7","first-page":"205","article-title":"The place of thiothixene among the thioxanthenes","volume":"14","author":"Sterlin","year":"1972","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0008|cit8","first-page":"175","article-title":"[Title only available in Chinese characters]","volume":"18","author":"\u5218\u542f\u73cd","year":"2005","journal-title":"Shandong Archives of Psychiatry [\u5c71\u4e1c\u7cbe\u795e\u533b\u5b66]"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0009|cit9","first-page":"169","article-title":"A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population","volume":"10","author":"Dehnel","year":"1968","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Fagerlund B Mackeprang T Gade A Hemmingsen R Glenthoj BY Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in fisrt-episode drug-naive schizophrenic patients CNS Spectrums 2004 364 74 15115949","DOI":"10.1017\/S1092852900009354"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0011|cit11","first-page":"34","article-title":"An example of European multicentre trials: multispectral analysis of clozapine","volume":"12","author":"Fischer-Cornelssen","year":"1976","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pscychresns.2006.10.002","article-title":"Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug","volume":"154","author":"Glenthoj","year":"2007","journal-title":"Psychiatry Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005474.pub2-BIB0013|cit13","first-page":"6","article-title":"Extrastriatal dopamine D2\/D3-receptors in drug-na\u00efve first-episode schizophrenic patients: relation to psychopathology, cognition and treatment outcome","volume":"11","author":"Glenthoj","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0014|cit14","unstructured":"Glenthoj B Glenthoj A Jagersma E Pagsberg AK Hemmingsen RP Svarer C Effects of typical and atypical antipsychotic medication on caudate nucleus volume in first-episode schizophrenic patients: relation to dopamine d2\/3 receptor occupancy psychopathology and extrapyramidal side-effects Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt 2005"},{"issue":"5","key":"10.1002\/14651858.CD005474.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1600-0447.1978.tb03570.x","article-title":"Cis(Z)-clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. A double-blind clinical investigation","volume":"58","author":"Gravem","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0016|cit16","first-page":"13","article-title":"Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. A double-blind clinical investigation","volume":"294","author":"Gravem","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0447.1981.tb06210.x","article-title":"A double-blind clinical investigation of cis(Z)-clopenthixol and clopenthixol in chronic schizophrenic patients","volume":"294","author":"Heikkila","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"9","key":"10.1002\/14651858.CD005474.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1185\/03007999209111526","article-title":"Zuclopenthixol and haloperidol in patients with acute psychotic states. A double-blind, multicentre study","volume":"12","author":"Heikkila","year":"1992","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1600-0447.1981.tb06211.x","article-title":"Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation","volume":"294","author":"Heikkila","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0447.1995.tb09781.x","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial","volume":"91","author":"Huttunen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005474.pub2-BIB0021|cit21","first-page":"85","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes","volume":"9","author":"Huttunen","year":"1994","journal-title":"European Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0022|cit22","first-page":"106","article-title":"The prevalence of extrapyramidal symptoms during short and long term treatment with risperidone","volume":"11","author":"Moller","year":"1994","journal-title":"7th Biennial European Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0023|cit23","first-page":"41","article-title":"Double blind study of clopenthixol and chlorpromazine in acute hospitalized schizophrenics","volume":"3","author":"Kingstone","year":"1970","journal-title":"Internationale Zeitschrift Fur Klinische Pharmakologie Therapie und Toxikologie"},{"issue":"512","key":"10.1002\/14651858.CD005474.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1192\/bjp.114.512.833","article-title":"Clopenthixol: a controlled trial in chronic hospitalized schizophrenic patients","volume":"114","author":"Kordas","year":"1968","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0025|cit25","first-page":"13","article-title":"A multicentre comparison of oral zuclopenthixol dihydrochloride and oral sulpiride in the treatment of acute schizophrenia","volume":"2","author":"Mahadevan","year":"1991","journal-title":"British Journal of Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-1017093","article-title":"Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study","volume":"20","author":"Remvig","year":"1987","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0031|cit27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000467995","article-title":"Consistency and similarity of drug EEG responses in chronic schizophrenic patients","volume":"8","author":"Serafetinides","year":"1973","journal-title":"International Pharmacopsychiatry"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0032|cit28","first-page":"190","article-title":"Voltage laterality in the EEG of psychiatric patients","volume":"34","author":"Serafetinides","year":"1973","journal-title":"Diseases of the Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0027|cit29","first-page":"263","article-title":"Psychological effects of single dose antipsychotic medication","volume":"7","author":"Serafetinides","year":"1973","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0028|cit30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00005053-197201000-00005","article-title":"Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives","volume":"154","author":"Serafetinides","year":"1972","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0030|cit31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000468000","article-title":"A method of quantifying EEG for psychopharmacological research","volume":"8","author":"Serafetinides","year":"1973","journal-title":"International Pharmacopsychiatry"},{"issue":"5","key":"10.1002\/14651858.CD005474.pub2-BIB0029|cit32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005053-197211000-00010","article-title":"Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia","volume":"155","author":"Serafetinides","year":"1972","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0033|cit33","unstructured":"Wang R Double blind study of clopenthixsol treating schizophrenia Medical Journal of Chinese Civil Administration 1995 4-5, 7"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0447.1981.tb06215.x","article-title":"Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers","volume":"294","author":"Aaes-Jorgensen","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0447.1980.tb07085.x","article-title":"Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial","volume":"279","author":"Ahlfors","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0036|cit36","first-page":"44","article-title":"Zuclopenthixol versus haloperidol in the initial treatment of schizophrenic psychoses,affective psychoses and paranoid states: a controlled clinical trial","volume":"7","author":"Al Haddad","year":"1996","journal-title":"Arab Journal of Psychiatry"},{"issue":"3 Suppl.1","key":"10.1002\/14651858.CD005474.pub2-BIB0037|cit37","first-page":"233","article-title":"Prediction and prevention of violence in schizophrenia outpatients: preliminary report","volume":"53","author":"Arango","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0447.1993.tb03329.x","article-title":"A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis","volume":"37","author":"Baastrup","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0039|cit39","first-page":"61","article-title":"The use of oral zuclopenthixol in the treatment of functional psychotic illness","volume":"5","author":"Bereen","year":"1987","journal-title":"Pharmatherapeutica"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0040|cit40","first-page":"1","article-title":"Acute functional psychoses:treatment with zuclopenthixol dihydrochloride ('Clopixol') tablets","volume":"5","author":"Bhattacharya","year":"1987","journal-title":"Pharmatherapeutica"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0041|cit41","unstructured":"Bobon D de Bleeker E Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study 2nd Congress of the European College of Neuropsychopharmacology; 1989 May 24-26; Gothenburg, Germany 1989 76021805"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0042|cit42","unstructured":"Bobon D de Bleeker E Zuclopenthixol acetate and haloperidol in acute psychotic patients - a randomized multicentre study New Strategies in the Treatment of Aggressive, Acutely Psychotic Patients. Proceedings of the 8th World Congress of Psychiatry; 1989 October 13-19, Athens, Greece Excerpta Medica 1989 47 59 76021805"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0043|cit43","first-page":"236","article-title":"Zuclopenthixol acetate and haloperidol in acute psychoses - results of the AMDP subgroup of a Belgian multicenter study","volume":"87","author":"Bourdouxhe","year":"1987","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Brook S Berk M Selemani S Kolloori J Nzo I A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1997 95351128","DOI":"10.1002\/(SICI)1099-1077(199801)13:1<17::AID-HUP937>3.0.CO;2-G"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Brook S Berk M Selemani S Kolloori J Nzo I A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis Unpublished Report submitted to Human Psychopharmacology Clinical and Experimental 1996 95351128","DOI":"10.1016\/S0924-977X(97)88643-9"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1099-1077(199801)13:1<17::AID-HUP937>3.0.CO;2-G","article-title":"A randomized controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis","volume":"13","author":"Brook","year":"1998","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0047|cit47","first-page":"449","article-title":"Improved antisaccade performance with risperidone in schizophrenia","volume":"72","author":"Burke","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0048|cit48","first-page":"365","article-title":"A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics","volume":"53","author":"Chin","year":"1998","journal-title":"Medical Journal of Malaysia"},{"issue":"6","key":"10.1002\/14651858.CD005474.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00004714-199412000-00002","article-title":"A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation","volume":"14","author":"Chouinard","year":"1994","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0050|cit50","unstructured":"Chouinard G Safadi G Beauclair L The management of acutely schizophrenic patients newly admitted from the emergency room: a double-blind clinical trial comparing zuclopenthixol acetate and liquid haloperidol Modern Trends in the Treatment of Chronic Schizophrenia. Proceedings of a Symposium; 1991 June 10, Florence, Italy Excerpta Medica 1991 35 43 95190073"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0051|cit51","first-page":"54","article-title":"Sordinol versus chlorpromazine versus placebo","volume":"3","author":"Clark","year":"1969","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0052|cit52","unstructured":"CTRI-2014-07-004712 Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine Http:\/\/apps.who.int\/trialsearch\/Trial.aspx?TrialID=CTRI\/2014\/07\/004712 2014"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0053|cit53","unstructured":"Mythri SV Tharyan P Sunder S Kattula D Kirubakaran R Adams CE Rapid tranquillization of violent or agitated patients in a psychiatric emergency setting: Pragmatic, randomized, allocation concealed, participant and assessor blinded trial of intramuscular zuclopenthixol acetate versus intramuscular haloperidol plus promethazine Study Protocol 2013"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N","article-title":"Ritanserin as add on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia","volume":"15","author":"Boer","year":"2000","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-0447.1980.tb07080.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate","volume":"279","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0447.1980.tb07083.x","article-title":"Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome","volume":"279","author":"Dencker","year":"1980","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0447.1978.tb06898.x","article-title":"Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot","volume":"57","author":"Dom","year":"1978","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0920-9964(03)80924-6","article-title":"Effects of risperidone and zuclopenthixol on cognitive deficits in drug-naive first episode schizophrenic patients","volume":"60","author":"Fagerlund","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0059|cit59","unstructured":"Fan S Sun ZG Li J The comparison of effects of clopenthixal and clozapine in the treatment of schizophrenia Acta Acadimae Medicinae Qingdao 1999 125 7"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08039489009096565","article-title":"Zuclopenthixol acetate, haloperidol, and zuclopenthixol in the treatment of acutely psychotic patients - A controlled multicenter study. Meeting of the Scandinavian Society for Psychopharmacology (1989, Copenhagen, Denmark)","volume":"44","author":"Fensbo","year":"1990","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Fricchione Parise V Balletta G Manna G Risperidone depot versus zuclopenthixol depot for schizophrenia and schizophrenialike psychoses: Real world outcomes European Neuropsychopharmacology 2010 472 3","DOI":"10.1016\/S0924-977X(10)70696-9"},{"issue":"6","key":"10.1002\/14651858.CD005474.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0006-3223(94)90002-7","article-title":"QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients","volume":"35","author":"Galderisi","year":"1994","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0064|cit63","unstructured":"Glenthoj BY Mackeprang T Fagerlund B Hemmingsen R Effects of antipsychotics on information-processing and extrastriatal dopamine d2\/d3 receptors in first-episode drug-naive schizophrenic patients 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico 2000 191 95275743"},{"issue":"1,2","key":"10.1002\/14651858.CD005474.pub2-BIB0063|cit64","first-page":"133","article-title":"Effects of antipsychotic treatment on prepulse inhibition of the startle response (ppi) and cognition in first episode drug-naive schizophrenic patients","volume":"49","author":"Glenth\u00a2j","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"294","key":"10.1002\/14651858.CD005474.pub2-BIB0065|cit65","first-page":"5","article-title":"Cis(Z) clopenthixol. The neuroleptically active isomer of clopenthixol. A presentation of five double blind clinical investigations and other studies with cis(Z) clopenthixol (Cisordinol(R), Clopixol(R))","volume":"64","author":"Gravem","year":"1981","journal-title":"Acta Psychiatrica Scandinavica, Supplementum"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/08039489009096586","article-title":"Co-injection of zuclopenthixol acetate and zuclopenthixol decanoate","volume":"44","author":"Gravem","year":"1990","journal-title":"Nordisk Psykiatrisk Tidsskrift"},{"issue":"19","key":"10.1002\/14651858.CD005474.pub2-BIB0067|cit67","first-page":"615","article-title":"Retrospective and prospective studies on the clinical effect of clopenthixol (sordinol) in endogenous phychoses","volume":"97","author":"Hicklin","year":"1967","journal-title":"Schweizerische Medizinische Wochenschrift. Journal Suisse De Medecine"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0068|cit68","first-page":"S293","article-title":"Risperidone versus zuclopenthixol in acute psychosis in emergency psychiatry: a prospective naturalistic study","volume":"13","author":"Hovens","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Hovens JE Dries PJT Melman CTM Wapenaar RJC Loonen AJM Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study Journal of Psychopharmacology 2005 51 7 15671129","DOI":"10.1177\/0269881105048897"},{"issue":"10","key":"10.1002\/14651858.CD005474.pub2-BIB0070|cit70","first-page":"775","article-title":"Comparison of clopenthixol decanoate to chlorpromazine in the treatment of schizophrenia","volume":"4","author":"Huang","year":"2001","journal-title":"Chinese General Practice"},{"issue":"64","key":"10.1002\/14651858.CD005474.pub2-BIB0071|cit71","first-page":"39","article-title":"Neuroleptic treatment of oligophrenic patients. A double-blind clinical multicentre trial of cis(Z)-clopenthixol and haloperidol","volume":"294","author":"Karsten","year":"1981","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD005474.pub2-BIB0072|cit72","first-page":"163","article-title":"Sexual dysfunctions and serum prolactin levels in patients using risperidone or quetiapine: a randomised trial","volume":"53","author":"Knegtering","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0073|cit73","unstructured":"Koskinen T Wistedt B Thelander S Zuclopenthixol decanoate vs haloperidol decanoate: a double-blind comparative trial 5th World Congress of Biological Psychiatry; 1991 Jun 9-14; Florence, Italy 1991 563 5 95275743"},{"issue":"1,2","key":"10.1002\/14651858.CD005474.pub2-BIB0074|cit74","first-page":"216","article-title":"Effects of antipsychotics and other agents on prepulse inhibition of the starlte response(ppi)","volume":"49","author":"Kristiansen","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Kristiansen KT Mackeprang T Glenthoj BY Acute effects of antipsychotics and diazepam on prepulse inhibition of the startle response Schizophrenia Research 2003 100","DOI":"10.1016\/S0920-9964(03)80684-9"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/13651500310000906","article-title":"Zuclopenthixol versus haloperidol: an observational randomised pharmacoeconomic evaluation of patients with chronic schizophrenia exhibiting acute psychosis","volume":"7","author":"Lamure","year":"2003","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0077|cit77","unstructured":"Lemmens P De Smedt G Gheuens J Tritsmans L Efficacy of risperidone in the treatment of schizophrenia Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland 1994 106"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0078|cit78","unstructured":"Liu P Bian H Chen H Observation of clinical effect of clopixol-acuphase injection for acute psychosis Chinese Journal of Pharmaco Epidemiology [\u836f\u7269\u6d41\u884c\u75c5\u5b66\u6742\u5fd7] 1997 202 4"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0079|cit79","unstructured":"Liu S A follow-up of effects of sustain treatment of clopixol and cpz in schizophrenic patients Sichuan Mental Health [\u56db\u5ddd\u7cbe\u795e\u536b\u751f] 1998 162 3"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0080|cit80","first-page":"285","article-title":"Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on wcst and dichotic listening scores","volume":"11","author":"Loza","year":"2001","journal-title":"European Neuropsychopharmacology (Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey)"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0924-977X(91)90008-I","article-title":"Zuclopenthixol, a combined dopamine D1\/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia","volume":"1","author":"Lublin","year":"1991","journal-title":"European Neuropsychopharmacology"},{"issue":"Suppl.1,2","key":"10.1002\/14651858.CD005474.pub2-BIB0082|cit82","first-page":"194","article-title":"Extrastriatal dopamine(d2\/d3)-receptor occupancy and cognition in first episode schizophrenic patients","volume":"49","author":"Mackeprang","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1192\/bjp.166.3.374","article-title":"Effectiveness of zuclopenthixol compared with haloperidol in the treatment of behavioural disturbances in learning disabled patients","volume":"166","author":"Malt","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD005474.pub2-BIB0084|cit84","first-page":"386392","article-title":"A clinical assessment of zuclopenthixol dihydrochloride ('Clopixol Tablets') in the treatment of psychotic illness","volume":"4","author":"Mann","year":"1985","journal-title":"Pharmatherapeutica"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0085|cit85","first-page":"110","article-title":"The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry","volume":"12","author":"Martyns Yellowe","year":"1993","journal-title":"West African Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0086|cit86","first-page":"200","article-title":"The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment","volume":"13","author":"Martyns-Yellowe","year":"1994","journal-title":"West African Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1016\/S0924-977X(03)92108-0","article-title":"Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia","volume":"13","author":"Mazurek","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"26","key":"10.1002\/14651858.CD005474.pub2-BIB0088|cit88","first-page":"869","article-title":"Rediscovery of a neuroleptic drug in a new form: clopenthixol","volume":"61","author":"Meyers","year":"1972","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0089|cit89","first-page":"47","article-title":"Effect and tolerability of Clopixol and haloperidol in patients with acute symptoms of schizophrenia: comparative randomized investigation","volume":"10","author":"Mosolov","year":"2000","journal-title":"Sotsial'Naia I KlinIcheskaia Psikhiatria"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0090|cit90","unstructured":"NCT00206960 Effects of classical and atypical antipsychotics on dopamine receptor binding of 123i-epidepride, cognition, startle response and extrapyramidal side-effects in drug-naive first-episode schizophrenic patients http:\/\/www.clinicaltrials.gov 2005"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0091|cit91","first-page":"99","article-title":"Change in caudate nucleus volume after three-month treatment in drug- naive first-episode schizophrenia patients","volume":"67","author":"Pagsberg","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0092|cit92","unstructured":"Ropert R Hoepfner Petersen HE Benyay J Where zuclopenthixol acetate stands amid the 'modified release' neuroleptics Congres de Psychiatrie et de Neurologie de Langue Francaise, LXXXVIth Session; 1988 Jun 13-17; Chambery, France 1988 350 62 87290070"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005474.pub2-BIB0093|cit93","first-page":"S476","article-title":"Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term controlled study","volume":"15","author":"Rubio","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Rubio G Martinez I Ponce G Jimenez-Arriero MA Lopez-Munoz F Alamo C Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie] 2006 531 9 16933590","DOI":"10.1177\/070674370605100808"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0095|cit95","unstructured":"Rubio G Martinez-Gras I Ponce G Jim\u00e9nez-Arriero MA L\u00f3pez-Mu\u00f1oz F Alamo C Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada 2006"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0096|cit96","unstructured":"Rubio G Rodriguez-Jimenez R Martinez-Gras I Jimenez-Arriero MA Palomo T Prepulse inhibition of the startle response in amisulpride-treated patients: comparison with typical antipsychotics Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28-Jul 2 ;Paris, France 2009 394"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0097|cit97","first-page":"133","article-title":"Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study","volume":"20","author":"Rubioz","year":"2006","journal-title":"European Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0098|cit98","unstructured":"Saxena B MacCrimmon D Busse E Turner P Cooper L Kenny J I.M clopixol v\/s modecate in chronic schizophrenia - a double-blind study Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan 1990 247"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0099|cit99","unstructured":"Saxena B The value of depot neuroleptic injections in the treatment of chronic schizophrenia Schizophrenia 1996 - Breaking down the Barriers. Proceedings of the 4th International Conference; 1996 Oct 6-9; Vancouver, Canada 1996 73210072"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0920-9964(93)90598-D","article-title":"Treatment strategies in schizophrenia: effects of dosage reduction and family management on outcome","volume":"9","author":"Schooler","year":"1993","journal-title":"International Congress on Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0101|cit101","first-page":"22","article-title":"The Achilles reflex and antipsychotic drugs","volume":"11","author":"Shelton","year":"1969","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2788.1992.tb00572.x","article-title":"A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural disorders","volume":"36","author":"Singh","year":"1992","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Sofronov A Spikina A Savelyev A The role of modern antipsychotics in correction of neurocognitive deficit in schizophrenia patients European Psychiatry 2013 1247","DOI":"10.1016\/S0924-9338(13)76320-X"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0104|cit104","first-page":"35","article-title":"Controlled cross-over comparison of oxyprothepine and clopenthixol decanoate in the prophylaxis of schizophrenic psychoses","volume":"28","author":"Svestka","year":"1986","journal-title":"Activitas Nervosa Superior"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/030006059702500104","article-title":"Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients","volume":"25","author":"Syvalahti","year":"1997","journal-title":"Journal of International Medical Research"},{"issue":"12","key":"10.1002\/14651858.CD005474.pub2-BIB0106|cit106","first-page":"1301","article-title":"Comparative study of the effectiveness of zuclopenthixol acetate and haloperidol in acutely disturbed psychotic patients","volume":"85","author":"Taymeeyapradit","year":"2002","journal-title":"Journal of the Medical Association of Thailand"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-2007-1017319","article-title":"A comparative trial of Cis(Z)-clopenthixol-decanoate and fluphenazine-decanoate","volume":"18","author":"Tegeler","year":"1985","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Uys H Berk M A controlled double blind study of zuclopenthixol acetate compared to clothiapine in acute psychosis including mania and exacerbation of chronic psychosis Unpublished Report 1996 74083340","DOI":"10.1016\/0924-977X(96)87580-8"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Uys H Berk M A controlled double blind study of zuclopenthixol acetate compared with clothiapine in acute psychosis including mania and exacerbation of chronic psychosis 20th Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1996 Jun 23-27; Melbourne, Australia 1996 74083340","DOI":"10.1016\/0924-977X(96)87580-8"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/gps.930050410","article-title":"Zuclopenthixol dihydrochloride in the management of behavioural disorders in elderly demented patients:a dose-ranging study","volume":"5","author":"Venkateswarlu","year":"1990","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00174677","article-title":"Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate","volume":"94","author":"Viala","year":"1988","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD005474.pub2-BIB0112|cit112","first-page":"289","article-title":"A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out- patients","volume":"3","author":"Walker","year":"1983","journal-title":"Pharmatherapeutica"},{"issue":"11","key":"10.1002\/14651858.CD005474.pub2-BIB0113|cit113","first-page":"1845","article-title":"Advantages of the initial therapy of acute schizophrenia with large doses of droperidol\/A comparative study (author's transl)","volume":"25","author":"Weiser","year":"1975","journal-title":"Arzneimittel Forschung"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0114|cit114","doi-asserted-by":"crossref","unstructured":"Wistedt B Koskinen T Thelander S Pedersen V Molberg C Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia - a double-blind, multicenter study Psychopharmacology 1990 23","DOI":"10.1111\/j.1600-0447.1991.tb01414.x"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.1991.tb01414.x","article-title":"Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study","volume":"84","author":"Wistedt","year":"1991","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0116|cit116","first-page":"202","article-title":"Efficacy of clopenthixol in treating delusions and halucinations in schizophrenia","volume":"9","author":"Xiaanoao","year":"1999","journal-title":"Journal of Clinical Psychology"},{"issue":"suppl.2","key":"10.1002\/14651858.CD005474.pub2-BIB0117|cit117","first-page":"S16","article-title":"Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate","volume":"14","author":"Youssef","year":"1991","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00019053-199711010-00005","article-title":"Measuring quality of life in patients with schizophrenia","volume":"11","author":"Awad","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0121|cit121","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0122|cit122","first-page":"233","article-title":"The Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001164","article-title":"Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses","author":"Silva Freire Coutinho","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0124|cit124","volume-title":"Chemotherapy of Psychiatric Disorders","author":"Dally","year":"1967"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0125|cit125","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD005474.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.1999.00908.x","article-title":"Drug discovery and development in the molecular era","volume":"47","author":"Dollery","year":"January 1999","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD005474.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0133|cit133","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0135|cit135","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD005474.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"Monograph Suppl","key":"10.1002\/14651858.CD005474.pub2-BIB0137|cit137","first-page":"1","article-title":"Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study","volume":"20","author":"Jablensky","year":"1992","journal-title":"Psychological Medicine"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000525.pub3","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","author":"Jayakody","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0139|cit139","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD005474.pub2-BIB0141|cit141","first-page":"25","article-title":"Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects).","volume":"103","author":"Kozyrev","year":"2003","journal-title":"Zhurnal Nevrologii Psikhiatrii Im S S Korsakova"},{"issue":"11","key":"10.1002\/14651858.CD005474.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD005474.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"334","key":"10.1002\/14651858.CD005474.pub2-BIB0145|cit145","first-page":"100","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD005474.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13651500510028995","article-title":"A prescription survey of antipsychotic use in England and Wales following the introduction of NICE guidance","volume":"9","author":"Mace","year":"2005","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"3","key":"10.1002\/14651858.CD005474.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2005-864124","article-title":"Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy","volume":"38","author":"Percudani M. Barbui C. Fortino I. Petrovich","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0152|cit152","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1192\/pb.24.3.106","article-title":"Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol","volume":"24","author":"Taylor","year":"2000","journal-title":"Psychiatric Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD005474.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD005474.pub2-BIB0155|cit155","volume-title":"Pocket Guide to the ICD-10 Classification of Mental and Behavioural Disorders","author":"Multiple","year":"2010"},{"issue":"7","key":"10.1002\/14651858.CD005474.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD005474.pub2-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005474","article-title":"Zuclopenthixol dihydrochloride for schizophrenia","author":"Kumar","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD005474.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:18:12Z","timestamp":1719584292000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005474.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":157,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005474.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]}}}